Current developments in small cell lung cancer
DOI:
https://doi.org/10.37609/srinmed.9Keywords:
lung cancer, small cell, treatmentAbstract
Small cell lung cancer (SCLC), often associated with smoking, is characterized by its aggressive biology and potential for early metastasis. It accounts for approximately 15% of all lung cancer patients. The combination of platinum-based chemotherapy and etoposide has been used for many years in the treatment of SCLC. The prognosis for patients with SCLC who are treated as a single group is still quite poor. Recent research has provided a new perspective on the biology of SCLC. A survival benefit has been demonstrated by adding immune checkpoint inhibitors to chemotherapy in patients with extensive stage SCLC.
The study of the molecular, biological, and immunological properties of the heterogeneous structure of SCLC is a promising area of research for the future. Identification of distinct gene expression profiles (ASCL1, NEUROD1, POU2F3, and YAP1) of SCLC patients may form the basis of the most effective and individualized therapeutic treatments in disease management. More research is needed to identify SCLC subtypes and develop effective treatments for this group of patients who have a poor prognosis.
References
Petty WJ, Paz-Ares L. Emerging strategies for the treatment of small cell lung cancer: a review. JAMA oncology. 2023;9(3):419-29.
Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies. International journal of cancer. 2012;131(5):1210-9.
Wang S, Tang J, Sun T, Zheng X, Li J, Sun H, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Scientific reports. 2017;7(1):1339.
Schwendenwein A, Megyesfalvi Z, Barany N, Valko Z, Bugyik E, Lang C, et al. Molecular profiles of small cell lung cancer subtypes: therapeutic implications. Molecular Therapy-Oncolytics. 2021;20:470-83.
Horvath L, Lang C, Boettiger K, Aigner C, Dome B, Megyesfalvi Z. Potential subtype-specific therapeutic approaches in small cell lung cancer. Current Opinion in Oncology. 2024;36(1):51-6.
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature genetics. 2012;44(10):1104-10.
Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer research. 1985;45(6):2913-23.
Zhang W, Girard L, Zhang Y-A, Haruki T, Papari-Zareei M, Stastny V, et al. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Translational lung cancer research. 2018;7(1):32.
Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer. 2019;19(5):289-97.
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory smallcell lung cancer: results from the phase II TRINITY
study. Clinical Cancer Research. 2019;25(23):6958-66.
Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. Journal of Thoracic Oncology. 2021;16(9):1547-58.
Paz-Ares L, Ahn M, Felip E, Handzhiev S, Korantzis I, Izumi H, et al. 508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study. Annals of Oncology. 2023;34:S1664-S5.
Huang Y-H, Klingbeil O, He X-Y, Wu XS, Arun G, Lu B, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes & development. 2018;32(13-14):915-28.
Micke P, Faldum A, Metz T, Beeh K-M, Bittinger F, Hengstler J-G, Buhl R. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung cancer. 2002;37(3):271-6.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(23):2220-9.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated
results from a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 2021;22(1):51-65.
Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. Journal of Thoracic Oncology. 2012;7(5):866-72.
Dingemans A-M, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks L, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2021;32(7):839-53.
Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer J, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of Clinical Oncology. 1999;17(2):658-.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. The Lancet Oncology. 2020;21(5):645-54.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Scientific Reports in Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Notice
Scientific Reports in Medicine is an open access scientific journal. Open access means that all content is freely available without charge to the user or his/her institution on the principle that making research freely available to the public supports a greater global exchange of knowledge. The Journal and content of this website is licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.
The Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allows users to copy, distribute and transmit an article, adapt the article and make noncommercial use of the article. The CC BY-NC-ND license permits non-commercial re-use of an open access article, as long as the author is properly attributed.
Scientific Reports in Medicine requires the author as the rights holder to sign and submit the journal's agreement form prior to acceptance. The authors transfer all financial rights, especially processing, reproduction, representation, printing, distribution, and online transmittal to Academician Publishing with no limitation whatsoever, and grant Academician Publishing for its publication. This ensures both that The Journal has the right to publish the article and that the author has confirmed various things including that it is their original work and that it is based on valid research.
Authors who publish with this journal agree to the following terms:
*Authors transfer copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
*Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
*Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Self Archiving Policy
*The Journal allows authors to self-archive their articles in an open access repository. The Journal considers publishing material where a pre-print or working paper has been previously mounted online. The Journal does not consider this an exception to our policy regarding the originality of the paper (not to be published elsewhere), since the open access repository doesn't have a publisher character, but an archiving system for the benefit of the public.
The Journal's policy regarding the accepted articles requires authors not to mention, in the archived articles in an open access repository, their acceptance for publication in the journal until the article is final and no modifications can be made. Authors are not allowed to submit the paper to another publisher while is still being evaluated for the Journal or is in the process of revision after the peer review decision.
The Journal does allow the authors to archive the final published article, often a pdf file, in an open access repository, after authors inform the editorial office. The final version of the article and its internet page contains information about copyright and how to cite the article. Only this final version of the article is uploaded online, on the Journal's official website, and only this version should be used for self-archiving and should replace the previous versions uploaded by authors in the open access repository.
